Other sex hormones and modulators of the genital system. Prasterone 6.5 mg.
PESSARIES: 28+ 6 vag. applicat. The recomm. dose is 6.5 mg prasterone (1 pess.) admin. once dly, at bedtime. the tmt. should be reassessed at least every 6 mnths. Missed dose, should be taken as soon as the pt. remembers. However, if the next dose is due in less than 8 hrs., the pt. should skip the missed pessary. Two pessar. should not be used to make up for a forgotten dose. See lit.
Treatment of vulvar and vaginal atrophy in postmenopaus. women having moder.-severe sympt.
C/I: Hypersens.
Undiagnosed genit. bleed.
Known, past or suspect. breast canc.
Known or suspect. oestrogen-dependent malig. tumours (e.g endomet.cancer).
Untreat. endomet. hyperplasia.
Acute liver dis., or a hist. of liver dis. as long as liver funct. tests have fail. to return to normal.
Previous/ current VT (DVT, PE).
Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin defic.).
Active or recent arterial thromboemb. dis. (e.g. angina, MI).
Porphyria.

Parathyroid hormone analogue. Teriparatide 20 mcg/dose.
STARTER BOX: (CARTRIDGE 2.4 ml×1 PEN×1). 20 mcg S.C. once daily.
Tmt. of Postmenopaus. Women with Osteoporos. at High Risk for Fract.
Tmt. of postmenopaus. women with osteoporos.  at high risk for fract., defined as a history of osteoporotic fract., multiple risk fact.  for fract., or pts. who have failed or are intoler. to other availab. osteoporosis ther. In postmenopaus. women with osteoporos., Terrosa incr. bone mineral densit. (BMD), reduces the risk of vertebr. and non-vertebr. fractures.
Incr. of Bone Mass in Men with Prim. or Hypogonadal Osteoporos.at High Risk for Fract.
Indicated to incr. bone mass in men with prim. or hypogonadal osteoporos. at high risk for fract., defined as a hist. of osteoporotic fract., multiple risk fact. for fract., or pts. who have failed or are intoler. to other availab. osteoporosis ther.
Tmt. of Men and Women with Glucocorticoid-Induc. Osteoporos. at High Risk for Fract.
Tmt. of men &women with osteoporosis assoc. with sustain.system. glucocorticoid ther. (daily dosage equiv. to 5 mg or greater of prednisone) at high risk for fract., defined as a hist. of osteoporotic fracture, multiple risk fact.  for fract., or pts. who have failed or are intoler. to other available osteoporosis ther.
C/I: Hypersens. See lit.

Calcitonin gene-related peptide (CGRP) antagonists.. Fremanezumab 225 mg.
PRE-FILL. SYR. (Sol.for  S.C. inj.):1, 3×1.5ml.
PRE-FILL PEN (Sol.for  S.C. inj.): 1, 3×1.5 ml. Tmt. is intend. for pts. with at least 4 migraine days per month when initiat. tmt. with fremanezumab.
Two dosing options are avail.:
225 mg once mnthly 675 mg every 3 mnths. (quarter. dosing)
When switch. dosing regimens, the 1^st  dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiating treatment with fremanezumab, concom. migraine prevent. tmt. may be contin. if consid. necessary by the prescriber .
The tmt. benefit should be assessed within 3 mnths. after initiat. of tmt. Any further decision to cont. tmt. should be taken on an individ. pt. basis. Evaluat. of the need to cont. tmt. is recomm. regularly thereafter.
Missed dose - dosing should resume as soon as possible on the indicat. dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicated for prophylax. of migraine in adults who have at least 4 migraine days per
month.
C/I: Hypersens. react. such as rash, pruritus, urticaria and swell. have been reported uncommon. with fremanezumab. Most react. were reported from within hrs. to one month after admin. and were mild – moder., but some led to discount. or required corticosteroid tmt. If a hypersens. reaction occurs, discount. of fremanezumab admin. should be consid.and appropriate ther. should be initiated.

 

TNF Blocking Agent. Adalimumab 50 mg/ml..
PRE-FILLED SYRINGE: 2 ×(20 mg/0.4 mL, 40mg/0.8ml)
PRE-FILLED PEN: 2× (40mg /0.8 ml).
Dosage ajust. individ. accord. to pt. med. condit.
RA: in comb. with methotrexate-tmt. of moder.-sev., active RA in adult pts. when the response to dis.-modif. anti-rheumat.drugs includ. methotrexate has been inadequate.
The tmt. of sev., active and progres. RA  in adult.not previous. treated with methotrexate,  given as monother. in case of intolerance to methotrexate or when continued tmt. with methotrexate is inappropr. AMGEVITA has been shown to reduce the rate of progress. of joint damage as measured by X-ray and to improve physical funct., when given in comb. with methotrexate.
Axial spondyloarthritis Ankylosing spond. (AS): tmt. of adult. with severe active AS who have had an inadeq. response to convent. ther.
Axial spondyloarthritis without radiograph. evidence of AS: tmt. of adults with sev. axial spondyloarthritis without radiograph.evidence of AS, but with object. signs of inflamm. by radiolog. and/or lab. tests includ. MRI and serum CRP levels, who have had an inadequate response to, or are intoler, to,NSAID’s.
Psoriatic arthritis: tmt. of active and progress. psoriat. arthritis in adults when the response to previous dis.-modif. anti-rheum.drug ther. has been inadequate. Adalimumab has been shown to reduce the rate of progress. of peripher. joint damage as measured by X-ray in pts. with polyarticular symmetr. subtypes of the dis. and to improve physic. func.
Psoriasis: tmt. of moder.-sev. chron. plaque psoriasis in adult pts. who are candidates for system. ther.
Hidradenitis suppurativa (HS): tmt. of active moder.- sev. hidradenitis suppurativa (acne inversa) in adult pts. with an inadequate response to convent. system. HS ther.
Crohn’s dis. : reducing signs and sympt.and induc.and maintain. clinical remiss. in adult pts. with moder.- sev. active Crohn’s dis. who have had an inadequate response to convent. ther. AMGEVITA is indic. for reduc. signs and sympt. and induc. clinical remiss. in these pts. if they have also lost response to or are intoler. to infliximab.
Ulcerat. colit.: tmt. of moder.-sev. active ulcerat. colit. in adult pts. who have had an inadequate response to convent. ther. includ. corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intoler. to or have med. contraindicat. for such therapies.
Uveitis : tmt. of non-infect. intermed., posterior and panuveitis in adult pts. who have had an inadequate response to corticosteroids, in pts. in need of corticosteroid-sparing, or in whom corticosteroid tmt. is inappropr.
Intestinal Behcet's dis.:  tmt. of intestin. Behcet’s dis. in pts. who have had an inadequate response to convention. ther.
C/I: Hypersens.
Active tuberculosis or other sev. infect. such as sepsis, and opportunist.infec.
Moder.-sev. HF(NYHA class III/IV).

Stabilizer of transthyretin.. Tafamidis 61 mg.
SOFT. CAPS.: 3×10. 61 mg (one  cap.) orally once dly,  swallow. whole and not crushed or cut., with/ without food.
Vyndamax and Vyndaqel (tafamidis meglumine) are not substitutab.on a per mg basis. Ped. use.: not indic. for child., adolesc. under 18 yrs. old. Geriat. use: No dosage adjust.is require.for elderly pts. (≥65 years).
Tmt. of the cardiomyopat. of wild type or heredit. transthyretin-mediated amyloidosis (ATTR-CM) in adult.to reduce cardiovasc. mortal. and cardiovasc.-related hospitalization.
C/I: Hypersens.

 

Monoclonal Antibody. Bevacizumab 25 mg/ml.
VIAL (Concent. for sol. for infus.):1×4 (100 mg),16 ml (400mg).
Dosage must be ajust. indivd. accord. to indicat. and pt. med. condit.
Tmt. of adult pts. with Metast.carcinoma of the colon or rectum: in comb.with fluoropyrimidine-based chemother.
1^ST -line tmt. of adult pts.  with metastat. breast cancer: in comb. with paclitaxel. For further informat., as to human epiderm. growth factor receptor 2 (HER2) status see lit.
1^ST -line tmt. of adult pts. with unresectable advance., metastat. or recur. non-small cell lung cancer other than predominant. squamous cell histology in addition to platinum-based chemother.
1^st -line tmt. of adult pts. with unresect. advanced, metastat. or recur. non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activat. mutations in comb. with erlotinib.
1^ST -line tmt. of adult pts. with advance. and/or metastat. renal cell cancer: in comb. with interferon alfa-2a.
Tmt.  of glioblastoma in pts. with progress. dis.  follow. prior ther. as a single agent.
Front-line tmt.  of advanced (FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer in pts. who are at high risk for recurrence (residual dis. after debulking): in comb. with carboplatin & paclitaxel. Tmt. of adult pts. with first recurrence of platinum-sensit. epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior ther. with bevacizumab or other VEGF inhib. or VEGF receptor-targeted agents: in comb. with carboplatin and gemcitabine, is indicat. for MVASI in comb. with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the tmt. of adult pts. with platinum-resist. recur. epithelial ovarian, fallopian tube, or prim. peritoneal cancer who received no more than two prior chemother. regimens and who have not received prior ther. with bevacizumab or other VEGF inhib. or VEGF receptor-targeted agents.
Tmt.  of adult pts. with persist., recur.,or metastat. carcinoma of the cervix,  in pts. who cannot receive platinum ther. in comb.with paclitaxel &cisplatin or, paclitaxel & topotecan.
C/I: Hypersens.
Hypersens. to Chinese Hamster Ovary (CHO) cell products or other recomb.human or humanized antibod.
Preg.